Abstract:
The authors present a study of 60 cases of cataract at
patients with uveitis associated with rheumatic diseases,
divided in two strands: the first composed of 30 patients
with uveitis, who followed a traditional treatment indicated
by the ophthalmologist and rheumatologist; the second – 30
patients with traditional treatment and Bevacizumab. The
data confirm that the treatment with Bevacizumab reduces
the risk of hemorrhagy complications during and postsurgery
at the patients with cataract associated with uveitis
and rheumatic diseases.